The "TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia" (TOPIC) trial was stopped preliminary, due to lagging inclusions. This study aimed to evaluate the treatment efficacy and clinical applicability of imiquimod 5% cream in high-grade cervical intraepithelial neoplasia (CIN). The lagging inclusions were mainly due to a strong patient preference for either of the two treatment modalities. This prompted us to initiate a new study on the same subject, with a non-randomized, open-label design: the 'TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC)-3' study. Original TOPIC-trial: Medical Ethics Committee approval number METC13231; ClinicalTrials.gov Identifier: NCT02329171, 22 December 2014. TOPIC-3 study: Medical Ethics Committee approval number METC162025; ClinicalTrials.gov Identifier: NCT02917746, 16 September 2016..

Additional Metadata
Keywords Biological markers, Cervical intraepithelial neoplasia, Human papillomavirus, Imiquimod, Natural history
Persistent URL dx.doi.org/10.1186/s12885-017-3108-9, hdl.handle.net/1765/97893
Journal BMC Cancer
Citation
Koeneman, M.M, Kruse, A.J, Kooreman, L.F.S, Zur Hausen, A, Hopman, A.H.N, Sep, S.J.S, … Kruitwagen, R.F.M.P. (2017). Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. BMC Cancer, 17(1). doi:10.1186/s12885-017-3108-9